LILRB4 did not affect the proliferation and metastasis of multiple myeloma, but LILRB4 blocking antibody could prevent the binding of LILRB4 to its ligands, therefore, anti-LILRB4 could block its signal pathway to inhibit the RELT secretion, then alleviate bone damage. This evidence concerns the gene RELT and plasma cell myeloma.